Zentalis Pharmaceuticals (ZNTL) Share-based Compensation (2019 - 2026)

Zentalis Pharmaceuticals' Share-based Compensation history runs 8 years deep, the most recent figure standing at $3.2 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 50.71% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at -$3.3 million (up 48.18% YoY), while the FY2023 annual figure was $54.8 million, changed N/A from the prior year.
• Share-based Compensation for Q1 2026 stood at $3.2 million, up from -$17.6 million in the prior quarter.
• The five-year high for Share-based Compensation was $16.8 million in Q2 2022, with the low at -$37.2 million in Q4 2022.
• The 5-year median for Share-based Compensation is $10.3 million (2022), against an average of $3.4 million.
• The sharpest annual moves came in 2023 and 2024: Share-based Compensation soared 137.28% in 2023, then tumbled 358.69% in 2024.
• Zentalis Pharmaceuticals' Share-based Compensation stood at -$37.2 million in 2022, then jumped by 137.28% to $13.9 million in 2023, then plunged by 358.69% to -$35.9 million in 2024, then soared by 50.98% to -$17.6 million in 2025, then jumped by 118.16% to $3.2 million in 2026.
• Business Quant data shows ZNTL's Share-based Compensation at $3.2 million in Q1 2026, -$17.6 million in Q4 2025, and $4.8 million in Q3 2025.